A Randomized, Controlled, Evaluator-blinded, Multi-center Study to Evaluate LYS228 Pharmacokinetics, Clinical Response, Safety, and Tolerability in Patients With Complicated Intra-abdominal Infection
Phase of Trial: Phase II
Latest Information Update: 27 Dec 2018
Price : $35 *
At a glance
- Drugs LYS-228 (Primary)
- Indications Bacterial infections
- Focus Pharmacokinetics; Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 14 Dec 2018 Status changed from recruiting to discontinued as part of the out-licensure of the drug to Boston Pharmaceuticals, which will continue further clinical development of LYS228/BOS-228
- 21 Aug 2018 Planned End Date changed from 11 Sep 2019 to 29 Aug 2019.
- 21 Aug 2018 Planned primary completion date changed from 5 Mar 2019 to 29 Aug 2019.